Conference News

Preliminary results from a placebo-controlled trial of the antibiotic minocycline in children with fragile X syndrome suggest the drug alleviates some aspects of the disorder, according to research presented Friday at the International Meeting for Autism Research in Toronto.

Neuroscience funding has plateaued, so researchers need to squeeze every drop from existing data.

By studying pregnant women who already have a child with autism, researchers hope to understand how epigenetic changes — those that affect gene expression but don’t directly alter DNA — during pregnancy influences risk of the disorder.

Two new studies on oxytocin, the so-called ‘trust hormone,’ suggest new avenues for using the drug to treat autism.

The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.